NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Ethiodized oil

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Summary

Ethiodized oil is a contrast agent used in imaging procedures.

Brand Names
Lipiodol, Lipiodol Ultra Fluide
Generic Name
Ethiodized oil
DrugBank Accession Number
DB00965
Background

Ethiodized oil is used by injection as a radio-opaque contrast agent. The composition of the oil is comprised of iodine combined with ethyl esters of fatty acids of poppyseed oil. And although these esters are primarily as ethyl monoiodostearate and ethyl diiodostearate, the actual, specific structure is unknown.

Type
Small Molecule
Groups
Approved, Investigational
Synonyms
  • Ethiodized oil
  • Ethiodized oil injection
  • IODIZED ETHYL ESTERS OF POPPYSEED FATTY ACIDS
External IDs
  • EOE 13
Unlock the secrets to drugging the undruggable
Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.
Download eBook
Unlock the secrets to drugging the undruggable
Download eBook

Pharmacology

Indication

For use as a radio-opaque medium for hysterosalpingography and lymphography, and as an antineoplastic agent when part of the iodine is 131-I. It is also used in follow-up imaging for chemoembolization.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Diagnostic agentHepatocellular carcinoma•••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

There has been little detailed investigation of the metabolic fate of ethiodized oil in either man or animals. However, the fate of ethiodized oil following Iymphangiography in dogs has been reported. Koehler et al. employed I131-tagged ethiodol for lymphangiography in dogs and analyses of individual organs at various time intervals were done. The investigators reported an average of only 25% of the injected medium was retained in the lymphatics at the end of three days. An average of 50% was recovered from the lungs. They found the remainder of injected activity was fairly uniformly distributed throughout the body. Urinary excretion in the form of inorganic iodine was revealed as the chief mode of iodine loss from the system.

Mechanism of action

Ethiodized oil is selectively retained in tumor vessels for long periods, and is used for imaging organs such as liver, lung, stomach, and thyroid. Labeled with I-131 or other beta emitters (Y-90 or P-32), ethiodized oil can deliver a high internal radiation dose to certain tumors with minimal effect on healthy tissues.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Urinary excretion in the form of inorganic iodine was revealed as the chief mode of iodine loss from the system.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Intravenous LD50 in dog is 1580mg/kg. Symptoms of overdose include dyspnea and change in clotting factors.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AldesleukinThe risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Iodineunknown9679TC07X47553-56-2PNDPGZBMCMUPRI-UHFFFAOYSA-N
International/Other Brands
Ethiodol
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
EthiodolInjection475 mg/1mLIntralymphaticSavage Laboratories a division of Fougera Pharmaceuticals Inc.2007-02-282016-09-30US flag
LipiodolInjection480 mg/1mLIntra-arterial; Intralymphatic; IntrauterineGuerbet2014-03-21Not applicableUS flag
Lipiodol Ultra FluidLiquid380 mg / gIntracavitary; ParenteralGuerbet1977-12-31Not applicableCanada flag
Lipiodol Ultra-FluideInjection480 mg/1mLIntra-arterial; Intralymphatic; IntramuscularDelpharm Tours2015-06-012019-04-01US flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
โอริโอดอลCapsule500 mgบริษัท แปซิฟิค เฮลธ์แคร์ (ไทยแลนด์) จำกัด2017-08-10Not applicableThailand flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Lipiodol Ultra-FluideEthiodized oil (480 mg/1mL)InjectionIntra-arterial; Intralymphatic; IntramuscularDelpharm Tours2015-06-012019-04-01US flag

Categories

ATC Codes
V08AD01 — Ethyl esters of iodised fatty acids
Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
KZW0R0686Q
CAS number
8008-53-5

References

General References
  1. Nelson RC: Techniques for computed tomography of the liver. Radiol Clin North Am. 1991 Nov;29(6):1199-212. [Article]
  2. Hamm B, Wolf KJ: Contrast material for computed tomography and magnetic resonance imaging of the gastrointestinal tract. Curr Opin Radiol. 1991 Jun;3(3):474-82. [Article]
  3. Link [Link]
KEGG Drug
D04082
PubChem Substance
46505147
RxNav
4125
ChEMBL
CHEMBL1201458
PharmGKB
PA164768833
RxList
RxList Drug Page
Wikipedia
Lipiodol
MSDS
Download (12.2 KB)

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
Not AvailableCompletedNot AvailableHCC / Portal Vein Tumor Thrombosis1somestatusstop reasonjust information to hide
Not AvailableCompletedNot AvailableHepatocellular Carcinoma1somestatusstop reasonjust information to hide
Not AvailableCompletedDiagnosticPulmonary Lesion With Ground-glass-opacity1somestatusstop reasonjust information to hide
Not AvailableCompletedTreatmentGastric Varices / Portal Hypertension1somestatusstop reasonjust information to hide
Not AvailableRecruitingNot AvailableHepatocellular Carcinoma1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
  • Guerbet llc
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntralymphatic475 mg/1mL
InjectionIntra-arterial; Intralymphatic; Intrauterine480 mg/1mL
SolutionIntra-arterial; Intralymphatic; Intramuscular; Intrauterine480 mg
LiquidIntracavitary; Parenteral380 mg / g
Injection, solutionIntralymphatic10 ml/10mL
Injection, solutionParenteral48 %
InjectionIntra-arterial; Intralymphatic; Intramuscular480 mg/1mL
Injection
Injection, solution
Injection, solution480 mg/10ml
SolutionIntra-arterial; Intralymphatic; Intramuscular960 mg/1ml
Capsule500 mg
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
boiling point (°C)125 °C (at 8mm Hg)Not Available
water solubilityInsolubleNot Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 13, 2005 13:24 / Updated at June 02, 2024 21:47